Collegium Pharmaceutical Revenue and Competitors
Estimated Revenue & Valuation
- Collegium Pharmaceutical's estimated annual revenue is currently $325.8M per year.
- Collegium Pharmaceutical's estimated revenue per employee is $1,374,599
- Collegium Pharmaceutical's total funding is $106M.
- Collegium Pharmaceutical's current valuation is $649.1M. (January 2022)
Employee Data
- Collegium Pharmaceutical has 237 Employees.
- Collegium Pharmaceutical grew their employee count by -1% last year.
Collegium Pharmaceutical's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Assistant to the CEO | Reveal Email/Phone |
2 | EVP, Head Technical Operations | Reveal Email/Phone |
3 | EVP, General Counsel & Chief Administrative Officer | Reveal Email/Phone |
4 | HEAD OF STRATEGY AND CORPORATE DEVELOPMENT | Reveal Email/Phone |
5 | VP, Corporate Communications | Reveal Email/Phone |
6 | VP, Commercial Operations | Reveal Email/Phone |
7 | HEAD OF HUMAN RESOURCES | Reveal Email/Phone |
8 | VP Finance | Reveal Email/Phone |
9 | VP, Market Access & Trade | Reveal Email/Phone |
10 | VP, Clinical Operations | Reveal Email/Phone |
Collegium Pharmaceutical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Collegium Pharmaceutical?
Collegium Pharmaceutical, Inc., is a privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products for the rapidly growing reformulation market and related areas. The Company's products target market opportunities through product improvement and line extension strategies protected by intellectual property (IP), creating a portfolio of improved pharmaceutical products. Collegium uses its broad expertise in IP development, drug formulation, manufacturing, basic science (chemistry, biology, bioengineering), marketing and clinical trials management to identify and execute product opportunities across multiple therapeutic areas.
keywords:N/A$106M
Total Funding
237
Number of Employees
$325.8M
Revenue (est)
-1%
Employee Growth %
$649.1M
Valuation
N/A
Accelerator
Collegium Pharmaceutical News
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio...
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio...
Collegium Pharmaceutical sees 65% growth in product revenue post BioDelivery acquisition: 2022 Guidance. Apr. 05, 2022 8:38 AM ETCollegium Pharmaceutical,...
STOUGHTON, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors has authorized the repurchase of up to $100 million of t ...
CANTON, Mass. — Collegium Pharmaceutical, the scrappy upstart taking on the mighty opioid maker Purdue Pharma, is having a moment. The company recently convinced Cigna, Humana, Navitus, and top health insurers in Florida and Pennsylvania to cover only its product Xtampza — and not Purdue’s infa ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $61.7M | 247 | 2% | N/A |
#2 | $49.1M | 248 | 8% | N/A |
#3 | $66.9M | 254 | 7% | N/A |
#4 | $66.9M | 268 | 6% | N/A |
#5 | $51.2M | 341 | 0% | N/A |